Currently, there are 76.15M common shares owned by the public and among those 46.04M shares have been available to trade.
The company’s stock has a 5-day price change of 37.04% and -8.30% over the past three months. CGON shares are trading -2.48% year to date (YTD), with the 12-month market performance down to -22.41% lower. It has a 12-month low price of $14.80 and touched a high of $46.99 over the same period. CGON has an average intraday trading volume of 878.21K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 37.64%, 15.53%, and -10.93% respectively.
Institutional ownership of Cg Oncology Inc (NASDAQ: CGON) shares accounts for 67.15% of the company’s 76.15M shares outstanding.
It has a market capitalization of $2.13B and a beta (3y monthly) value of 1.29. The earnings-per-share (ttm) stands at -$1.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.50% over the week and 10.33% over the month.
Earnings per share for the fiscal year are expected to decrease by -26.26%, and 11.18% over the next financial year.
Looking at the support for the CGON, a number of firms have released research notes about the stock. Scotiabank stated their Sector Perform rating for the stock in a research note on April 16, 2025, with the firm’s price target at $23. UBS was of a view on October 24, 2024 that the stock is Buy, while RBC Capital Mkts gave the stock Outperform rating on September 23, 2024, issuing a price target of $66. ROTH MKM on their part issued Buy rating on August 28, 2024.
